The main research directions in glioma immunotherapy currently include immune checkpoint inhibitors (such as PD-1/PD-L1 and CTLA-4 inhibitors), CAR-T cell therapy, tumor vaccines, and oncolytic viruses (3).The development of immunotherapy for gliomas has engendered new hope for the treatment of this refractory disease. This evidence concerns the gene CTLA4 and central nervous system cancer.